Myovant Sciences

-$0.06 (-0.62%) As of 5:31 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MYOV and other ETFs, options, and stocks.

About MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids.

CEO
David C. Marek
Employees
579
Headquarters
London, Greater London
Founded
2016

MYOV Key Statistics

Market cap
920.91M
Price-Earnings ratio
—
Dividend yield
—
Average volume
810.91K
High today
$10.19
Low today
$9.64
Open price
$9.83
Volume
191.25K
52 Week high
$27.43
52 Week low
$7.67

MYOV Earnings

-$0.99
-$0.66
-$0.33
$0.00
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Estimated
— per share
Actual
Expected Jul 28, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure